@groundhogy
My Gleason score was 3+4=7 and PSA < 10 (5.2) with MRI biopsy showing positive in two sides. That made me T2C, which in 2018, put me at "intermediate risk" and surgery was a valid option given my desire to get my PSA down to zero and not down to some "low" number. My post-surgery biopsy showed no seminal vesicle involvement, no lymph nodes, no extra-prostatic extension and the Gleason score matched the pre-surgery classification. Decipher genomic classifier test was NOT standard of care at that time and therefore the test was not run. Only after hitting the magical .2 number for recurrence did they run the Decipher test, which did inform the decision to add ADT to the treatment plan for 6 months. It would be easy to go back to 2018 and say I was high-risk based on a test from 2026. When I consulted with the radiation oncologist back then - the same one who just did my salvage treatments - he told me radiation would be well-tolerated but he could also tell that I remembered what happened to my dad, and how surgery was taken off the table once I opted for radiation. He actually ordered a genomic test on my first biopsy sample- the Oncotype DX test (which is no longer used) - and it said I was "low-risk" at .08. Talked to the oncology team today and they said I could explore the genetic testing if I wanted. I am married, but don't have kids, so I asked if it would shape my treatment in any way - and, right now - it probably wouldn't.